India's Biocon promises Herceptin biosim launch by year's end

Roche ($RHHBY) could have Indian competition for Herceptin sooner than it thought. Now that the Swiss drugmaker has decided to forego a patent fight over the breast cancer drug in India, domestic drugmakers are rubbing their hands together in anticipation. Bangalore-based Biocon says it's gearing up to launch its biosimilar version by the end of March. "We have completed the Phase III trials and are awaiting the result," CEO Kiran Mazumdar-Shaw said. "We are sure the product will be launched this financial year." Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.